- Home
- ANVS
ANVS
Annovis Bio Inc.
as 02-21-2025 4:00pm EST
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | MALVERN |
| Market Cap: | 92.6M | IPO Year: | 2020 |
| Target Price: | $31.40 | AVG Volume (30 days): | 684.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.08 - $20.00 | Next Earning Date: | 03-31-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Annovis Bio Inc. News
ANVS Breaking Stock News: Dive into ANVS Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Annovis to Host Patients’ Live Forum on February 27, 2025
GlobeNewswire
15 days ago
Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
Clinical Trials Arena
16 days ago
Annovis begins treatment of subjects in Alzheimer’s trial
TipRanks
16 days ago
Annovis Bio announces first patients entered Phase 3 study of buntanetap
MT Newswires
17 days ago
Annovis Bio Enrolls First Patients in Phase 3 Trial of Buntanetap for Early Alzheimer's Disease
GlobeNewswire
17 days ago
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease
GlobeNewswire
18 days ago
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering
MT Newswires
19 days ago
Top Midday Decliners
Compare ANVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANVS Annovis Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.